Drug Profile
Tocilizumab biosimilar - Mycenax Biotech
Alternative Names: LusiNEXLatest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Mycenax Biotech
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Immunosuppressants; Interleukin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Juvenile rheumatoid arthritis; Rheumatoid arthritis
Most Recent Events
- 28 May 2023 No recent reports of development identified for phase-I development in Juvenile-rheumatoid-arthritis in Taiwan (Parenteral)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in New Zealand (IV, Infusion)
- 28 Nov 2020 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in Australia (IV, Infusion)